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Transgenic mice overexpressing the P301L mutant
human tau protein exhibit an accumulation of hyper-
phosphorylated tau and develop neurofibrillary tangles.
The consequences of tau pathology were investigated
here by proteomics followed by functional analysis.
Mainly metabolism-related proteins including mito-
chondrial respiratory chain complex components, anti-
oxidant enzymes, and synaptic proteins were identified
as modified in the proteome pattern of P301L tau mice.
Significantly, the reduction in mitochondrial complex V
levels in the P301L tau mice revealed using proteomics
was also confirmed as decreased in human P301L
FTDP-17 (frontotemporal dementia with parkinsonism
linked to chromosome 17) brains. Functional analysis
demonstrated a mitochondrial dysfunction in P301L tau
mice together with reduced NADH-ubiquinone oxi-
doreductase activity and, with age, impaired mitochon-
drial respiration and ATP synthesis. Mitochondrial dys-
function was associated with higher levels of reactive
oxygen species in aged transgenic mice. Increased tau
pathology as in aged homozygous P301L tau mice re-
vealed modified lipid peroxidation levels and the up-
regulation of antioxidant enzymes in response to oxida-
tive stress. Furthermore, P301L tau mitochondria
displayed increased vulnerability toward -amyloid
(A) peptide insult, suggesting a synergistic action of
tau and A pathology on the mitochondria. Taken to-
gether, we conclude that tau pathology involves a mito-
chondrial and oxidative stress disorder possibly distinct
from that caused by A.
Alzheimer disease (AD)1 is characterized by two major his-
topathological hallmarks, extracellular plaques of fibrillar
-amyloid (A) peptides and intracellular neurofibrillary tan-
gles (NFTs) composed of hyperphosphorylated tau protein (1,
2). Mutations in tau have been identified in a related neurode-
generative disorder called frontotemporal dementia with par-
kinsonism linked to chromosome 17 (FTDP-17) with NFT for-
mation in the absence of plaque formation (3–5). Transgenic
mice overexpressing the P301L mutant human tau protein
were created to model tauopathies in vivo (6, 7). These mice
show an accumulation of hyperphosphorylated tau and NFT
formation similar to those in FTDP-17 and AD.
Little is known about the distinct intracellular mechanisms
underlying the consequences of tau pathology. This insight
could help us to understand the selective vulnerability of cells
with tau pathology and thereby the pathogenesis of AD. In-
creasing evidence highlights a connection between AD and
mitochondrial dysfunction together with a deregulation of en-
ergy metabolism and oxidative stress (8). Various reports have
demonstrated markedly reduced levels of mitochondrial pro-
teins and activities (9–11), decreased glucose turnover (12, 13),
increased mitochondrial DNA mutations (14–16), and in-
creased lipid peroxidation (17–19) in AD brains.
To examine the contribution of tau to these neurodegenera-
tive processes, we carried out a proteomic analysis of our P301L
tau transgenic mice. To zoom in on proteins relevant to the
pathology, we sequentially extracted whole brains from six
pairs of P301L tau and wild-type (WT) mice into three fractions
according to protein solubility. Comparative analysis of two-
dimensional gels run for each fraction revealed statistically
significant differences between P301L tau and WT mice. We
found three principal categories of proteins differentially reg-
ulated by P301L tau expression: metabolism-related proteins
including mitochondrial respiratory chain complex compo-
nents, oxidative stress-related enzymes implicated in reactive
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teins. Consistent with these findings, P301L tau mice exhibited
mitochondrial functional defects together with reduced elec-
tron transport chain complex I activity. Aged P301L tau mice
showed impaired mitochondrial respiration, reduced complex V
activity, and higher levels of ROS than WT controls. Further-
more, modified lipid peroxidation and increased antioxidant
enzyme activities were detected in aged homozygous mice. We
also found an increased vulnerability of P301L tau mitochon-
dria to A insult, suggesting a synergistic action of tau and A
pathology on the mitochondria. Corroborating the P301L tau
mouse mitochondrial deficits, we could demonstrate a reduc-
tion in complex V levels in human P301L FTDP-17 brains,
implying a potential mitochondrial dysfunction in human pa-
tients afflicted with this neurodegenerative disorder.
EXPERIMENTAL PROCEDURES
Transgenic Mice—The transgenic mice used in the present study
express the human pathogenic mutation P301L of tau together with the
longest human brain tau isoform (htau40) under control of the neuron-
specific mThy1.2 promoter (7). This isoform contains exons 2 and 3 as
well as four microtubule-binding repeats (234R, human tau40). Pro-
nuclear injections were done into C57Bl/6  DBA/2 F2 oocytes to obtain
founder animals that were back-crossed with C57Bl/6 mice to establish
transgenic lines. In addition, homozygous P301L tau mice were ob-
tained and confirmed by TaqMan real-time quantitative PCR (data not
shown).
Different age sets of mice were used for different experimental pro-
cedures corresponding to various stages in the development of tau
pathology. P301L tau mice show tau hyperphosphorylation already at 3
months (7). NFT formation starts at 6 months of age (20). We used
8.5–10-month-old mice for the proteomics analysis to study the conse-
quences of tau pathology at the beginning of NFT formation without the
influence of aging. At a similar age (i.e. 12 months old), mitochondrial
membrane potential and complex I and IV activity were determined.
ATP levels, mitochondrial respiration, and ROS levels were analyzed in
mice at 12 and 24 months of age. 24-month-old mice are expected to
bear the highest levels of tau pathology. 18-month-old mice were used
to determine mitochondrial numbers in neurites. This intermediate age
allows us to see the full effect of tau pathology on mitochondrial trans-
port without pronounced aging effects such as those seen in 24-month-
old mice. Finally, 12- and 24-month-old homozygous, hemizygous, and
wild-type mice were tested for lipid peroxidation.
Sequential Extraction of Brain Samples—Four pairs of 8.5-month-old
male hemizygous P301L tau and WT control mice and two pairs of
10-month-old male hemizygous P301L tau and WT control mice were
sacrificed by cervical dislocation, and brains were removed at 4 °C and
snap-frozen in liquid nitrogen. Brains were sequentially extracted with
the ReadyPrep sequential extraction kit (Bio-Rad) according to a mod-
ified version of the manufacturer’s protocol. Only one P301L tau and
oneWT each were extracted at a time. All steps were carried out at 4 °C,
unless otherwise specified. Briefly, whole brains were homogenized in 3
ml of buffer 1 (40 mM Tris, pH 7.4, Complete protease inhibitor mixture
(Roche Diagnostics), 0.5 mg/ml Pefabloc (Roche Applied Science), 1 mM
Na3V04, and 1 mM NaF) and 200 units of DNase I in a glass-Teflon
potter. After 15 min on ice, the homogenate was centrifuged at 15,000
g for 15 min. Supernatant E1 was collected for further analysis. The
pellet was washed twice with buffer 1 before it was resuspended in 750
l of buffer 2 (8 M urea, 4% CHAPS, 40 mM Tris, 0.2% Bio-Lyte 3/10
ampholytes (Bio-Rad), and 2 mM tributylphosphine), incubated for 10
min at room temperature, and ultra-centrifuged at 57,000  g for 30
min. Supernatant E2 was collected for further analysis. The pellet was
washed once with buffer 2 and then resuspended in buffer 3 (5 M urea,
2 M thiourea, 2% CHAPS, 2% caprylyl sulfobetaine 3–10, 40 mM Tris,
0.2% Bio-Lyte 3/10 ampholytes, and 2 mM tributylphosphine). The final
supernatant, E3, was collected after ultra-centrifugation at 89,000  g
for 30 min at 10 °C.
Two-dimensional Gel Electrophoresis—Isoelectrical focusing was
carried out using the PROTEAN IEF Cell (Bio-Rad). Six P301L tau
transgenic and six WT samples were focused simultaneously. Each
fraction from the sequential extraction (40 g of E1, 50 g of E2, or 60
l of E3) was loaded on 17-cm IPG strips (pH 3–10; Bio-Rad) in rehy-
dration buffer (8.5 M urea, 4% CHAPS, 0.5% pharmalytes (pH 3–10;
Amersham Biosciences), and 1.2% DeStreak reagent (Amersham Bio-
sciences). After passive rehydration for 15 h, the IPG strips were iso-
electrically focused following a stepwise increase in voltage from 150 to
10,000 V, finishing with 60,000 V-h. Prior to SDS-PAGE, the IPG strips
were equilibrated in 2% dithiothreitol, 6 M urea, 2% SDS, 0.05 M Tris,
pH 8.8, and 20% glycerol for 30 min and then equilibrated again in the
same buffer with 2.5% iodoacetamide instead of dithiothreitol for an-
other 30 min. Second dimension separation was performed on 12%
SDS-polyacrylamide gels at 200 V using the PROTEAN Plus Dodeca
cell electrophoresis system (Bio-Rad). All gels of the six P301L tau
transgenic and six WT samples from one fraction were run at the same
time.
Gel Staining and Image Analysis—Gels were stained using a modi-
fied silver staining method (21). Six P301L tau transgenic and six WT
two-dimensional gels were compared simultaneously with the Proteom-
weaver imaging software Version 2.1 (Definiens, Munich, Germany).
This software normalizes all gels and compares each two-dimensional
spot pattern of every transgenic gel of one fraction with each two-
dimensional spot pattern of every WT gel of the same fraction. Only
spots present in all 12 gels and differentially regulated by at least
1.5-fold were considered for statistical analysis with Student’s t test
(p  0.05).
Mass Spectrometry—For mass spectrometry analysis, 150 g of E1,
150 g of E2, and 180 l of E3, respectively, were loaded on 24-cm IPG
strips (pH 3–10). The two-dimensional gels were stained with Sypro
Ruby (Molecular Probes, Invitrogen), and the protein spots of interest
were excised with the GelPix protein spot excision system (Genetix,
Hampshire, UK). Spots were prepared for in-gel trypsin digestion.
Briefly, spots were washed twice with double-distilled H2O, once with
50 mM NH4HCO3/30% acetonitrile for 5 min at 37 °C, and once with
80% acetonitrile for 10 min at room temperature. Digestion was carried
out with 30 ng trypsin/spot in 10 mM Tris, pH 8.3, 2 mM CaCl2 for 3 h
at 37 °C. After 5 min of sonication, the tryptic digests were desalted and
concentrated using -C18 ZipTips (Millipore, Volketswil, Switzerland).
The bound peptides were eluted directly onto the MALDI target with
0.8 l of -cyano-4-hydroxycinnamic acid matrix (5 mg/ml) in 65%
acetonitrile, 35% double-distilled H2O containing 0.1% trifluoroacetic
acid. Digests were analyzed by MALDI tandem time-of-flight (TOF/
TOF) mass spectrometry using a 4700 Proteomics Analyzer MALDI-
TOF/TOFmass spectrometer (Applied Biosystems). One mass spectrum
and up to five tandem mass spectra of all precursor ions with a mini-
mum signal/noise ratio of 80 were recorded for each sample spot. Au-
toproteolytic fragments of trypsin were used as internal calibrants in
the mass spectrometry mode. The mass and tandem mass spectra were
analyzed using Mascot (Matrix Science, London, UK; available at www.
matrixscience.com) as the search engine. A combined mass spectrome-
try and tandemmass spectrometry search with a peptide tolerance of 25
ppm and a tandem mass spectrometry tolerance of 0.2 Da was carried
out against the UniProt complete mouse proteome data base (available
at ftp://ftp.ebi.ac.uk/pub/databases/integr8). Protein identification was
considered significant if the Mascot score was higher than the proba-
bility p  0.05 of a random match.
Evaluation of Complex V Level in Human Brains—Homogenates
from temporal cortex of two controls and four P301L FTDP-17 patients
were prepared in 150 mM Tris, pH 6.8, 2.5% SDS, 8 M urea, 20%
glycerol, 10% -mercaptoethanol, and 0.1% bromphenol blue and sub-
jected to Western blotting using standard methods. 2.5 l of total brain
lysate were loaded. The blots were developed with antibodies directed
against the complex V component ATP synthase chain D (A21343, 0.2
g/ml; Molecular Probes) and against porin for normalization (A31855,
0.2 g/ml; Molecular Probes). As a secondary antibody, a goat anti-
mouse IgG (Amersham Biosciences, 1:5000) was used. Non-overexposed
films were used to quantify the bands with Image J software (National
Institutes of Health; available at rsb.info.nih.gov/ij/). Complex V levels
were expressed as a percentage of porin levels.
Samples used (as loaded) were as follows: 1) control brain, 73-year-
old female; 2) control brain, 72-year-old male; 3) P301L brain, 64-year-old
female; 4) P301L brain, 52-year-old male; 5) P301L brain, 66-year-old
female; and 6) P301L brain, 60-year-old male. Three other control
samples were used (specifically, control temporal cortex from 78-year-
old female, 82-year-old female, and 78-year-old male brains) (data not
shown).
Materials Used for Mitochondrial Analysis—Rhodamine 123, tetra-
methylrhodamine-ethylester, and MitoTracker Green FM were pur-
chased from Molecular Probes Europe (Leiden, The Netherlands); 2,7-
dichlorodihydrofluorescein diacetate (H2DCF-DA) and dihydroethidium
(DHE) were purchased from Calbiochem (Merck Biosciences, Bad
Soden, Germany); hydrochloric acid, ethanol, ferric chloride, and chlo-
roform were purchased from VWR International (Darmstadt, Germa-
ny); and the ViaLight HT kit was purchased from Cambrex Bio Science
(Copenhagen, Denmark). The Cytochrome c Oxidase (Complex IV) As-
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say Kit, sodium nitroprusside, rotenone, thenoyltrifluoroacetone, anti-
mycin, sodium azide (NaN3), and oligomycin were obtained from Sigma-
Aldrich. A1–42 (Bachem, Weil am Rhein, Germany) was dissolved in
Tris-buffered saline, pH 7.4, at a concentration of 1 mM and stored at
20 °C. The stock solution was diluted in Tris-buffered saline to the
desired concentrations and incubated at 37 °C for 24 h to obtain aged,
aggregated preparations of A1–42. All aqueous solutions were prepared
with deionized and filtered water (Millipore).
Brain Tissue Preparation for Mitochondrial Analysis—Mice (8 pairs
of 12-month-old and 8 pairs of 24-month-old hemizygous P301L tau and
WT control mice) were sacrificed by decapitation, and brains were
quickly dissected on ice (described in Ref. 22, with modification). After
removing the cerebellum, one hemisphere (the other hemisphere was
directly used for preparation of isolated mitochondria) was minced into
1 ml of medium I (138 mM NaCl, 5.4 mM KCl, 0.17 mM Na2HPO4, 0.22
mM K2PO4, 5.5 mM glucose, and 58.4 mM sucrose, pH 7.35) with a
scalpel and further dissociated by trituration through a nylon mesh
(pore diameter, 1 mm) with a Pasteur pipette. The resulting suspension
was filtered by gravity through a fresh nylon mesh with a pore diameter
of 102 m, and the dissociated cell aggregates were washed twice with
medium II (110 mM NaCl, 5.3 mM KCl, 1.8 mM CaCl2H2O, 1 mM
MgCl26 H2O, 25 mM glucose, 70 mM sucrose, 20 mM HEPES, pH 7.4) by
centrifugation (400 g for 3 min at 4 °C). 100 l of the suspension were
used for protein determination. After centrifugation, cells were resus-
pended in 3 ml of Dulbecco’s modified Eagle’s medium, and then ali-
quots (100 l/well) were distributed in a white 96-well plate for meas-
urement of ATP levels, and aliquots (250 l/well) were distributed in a
48-well plate for measurement of the mitochondrial membrane poten-
tial and ROS levels. The latter were maintained at 37 °C in a humidi-
fied atmosphere of 5% CO2/95% air for the staining period with the
appropriate dye or incubated with A for 4 h. The preparations of
cortical cells from P301L tau transgenic mice and WT littermate con-
trols (crossover design) were made within 2 h under the same conditions
and in parallel. Data are expressed as fluorescence units per mg/ml
protein. The total protein content was determined (23).
Determination of the Mitochondrial Membrane Potential m—The
membrane potential of the inner mitochondrial membrane was meas-
ured using Rhodamine 123 dye added to the cell culture medium at a
final concentration of 0.4 M for 15 min. Cells were washed twice with
Hank’s balanced salt solution (Sigma), and fluorescence was deter-
mined with a Victor2 multiplate reader (PerkinElmer Life Sciences) at
490 nm (excitation)/535 nm (emission). Loading capacity of the dye
within the membrane decreases when the mitochondrial membrane
potential declines after damage, e.g. exposure to A1–42. For the sec-
ondary insult with A1–42, cells were incubated for 4 h with 50 nM
pre-aggregated A1–42.
To test acute and fast changes in m, the fluorescent dye tetrameth-
ylrhodamine-ethylester was used at 0.4 M for 15 min. Tetramethyl-
rhodamine-ethylester exhibits a characteristic increase in fluorescence
at 490 nm (excitation)/590 nm (emission) after challenging mitochon-
dria with drugs that decrease the membrane potential. The mitochon-
drial membrane potential was recorded with the respiratory inhibitors
rotenone (2 M), thenoyltrifluoroacetone (10 M), antimycin (2 M),
oligomycin (10 M), and sodium azide (10 mM) (24, 25).
ATP Levels—ATP levels were determined with a bioluminescence
assay (ViaLight HT; Cambrex Bio Science). The enzyme luciferase,
which catalyzes the formation of light from ATP and luciferin, was
utilized. The emitted light was linearly related to the ATP concentra-
tion and measured using a luminometer (26).
ROS Levels—Levels of cytosolic ROS were measured using the fluo-
rescent probe H2DCF-DA, and levels of superoxide anion radical were
measured by using DHE. Brain cells were loaded for 15 min with 10 M
H2DCF-DA or 10 M DHE. After washing twice with Hank’s balanced
salt solution, formation of the fluorescent product dichlorofluorescein
was detected with Victor2 multiplate reader (PerkinElmer Life Sci-
ences) at 485 nm (excitation)/535 nm (emission). Dichlorofluorescein is
trapped mainly in the cytoplasm and oxidized by several ROS, most
notably hydrogen peroxide (27). DHE, which is oxidized to the fluores-
cent ethidium cation by O2
. was detected with Victor2 multiplate reader
at 490 nm (excitation)/590 nm (emission) (28).
Amount of Mitochondria—The total amount of mitochondria was
measured using the cell-permeable mitochondrion-selective dye Mito-
Tracker Green FM (100 nM, 15 min) which is essentially nonfluorescent
in aqueous solutions and only becomes fluorescent once it accumulates
in the lipid environment of mitochondria (490 nm, excitation; 516 nm,
emission). To determine the number of mitochondria, in addition, four
pairs of 18-month-old P301L tau transgenic andWTmice were perfused
transcardially with 4% paraformaldehyde in microtubule stabilization
buffer (65 mM PIPES, 25 mM HEPES, 10 mM EGTA, and 3 mM MgCl2,
pH 6.9). 5-m paraffin brain sections were co-immunostained with
anti-porin (A31855, diluted 1:2000; Molecular Probes) and anti-tubulin
(YOL 1/34, 1:600; Abcam Limited, Cambridge, UK) antibodies, followed
by incubation with Cy3- and Cy2-conjugated secondary antibodies
(Jackson Immunoresearch, Milan Analytic, Fribourg, Switzerland). The
number of mitochondria in neurites of CA1 hippocampal neurons was
counted both proximal and distal to the cell body.
Preparation of Isolated Mitochondria—Mice were sacrificed by de-
capitation, and one brain hemisphere was rapidly dissected on ice and
washed in an ice-cold buffer (210 mM mannitol, 70 mM sucrose, 10 mM
HEPES, 1 mM EDTA, 0.45% bovine serum albumin, 0.5 mM dithiothre-
itol, and Complete protease inhibitor mixture tablets (Roche Diagnos-
tics)). After removing the cerebellum, the tissue sample was homoge-
nized in 2 ml of buffer with a glass homogenizer (10–15 strokes, 400
rpm), and the resulting homogenate was centrifuged at 1400  g for 7
min at 4 °C to remove nuclei and tissue particles. The low-speed cen-
trifugation step was repeated once with the supernatant. Then, the
supernatant fraction was centrifuged at 10,000  g for 5 min at 4 °C to
pellet mitochondria. The resulting pellet was resuspended in 1 ml of
ice-cold buffer and centrifuged again at 800  g for 3 min at 4 °C.
Finally, the mitochondria-enriched supernatant was centrifuged at
10,000  g for 5 min at 4 °C to obtain a mitochondrial fraction. This
fraction was resuspended in 100 l of ice-cold buffer and stored at 4 °C
until use, followed by determination of protein content (23).
Mitochondrial Respiration—The rate of mitochondrial respiration
was monitored at 25 °C using an Oxygraph-2k system (Oroboros, Inns-
bruck, Austria) equipped with two chambers and DatLab software.
Mitochondria (0.5 mg) were added to 2 ml of a buffer containing 65 mM
sucrose, 10 mM potassium phosphate, 10 mM Tris-HCl, 10 mM MgSO4,
FIG. 1. Representative two-dimensional gels. Six P301L tau and six WT brains were sequentially extracted. Fractions E1 (soluble proteins),
E2 (intermediate soluble), and E3 (less soluble) were separated by two-dimensional gel electrophoresis. Differential spot expression was evaluated
with Proteomweaver, and significantly regulated spots found between transgenic and wild-type two-dimensional gels were identified by mass
spectrometry. Representative gels of each fraction are shown.
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and 2 mM EDTA, pH 7.0. State 4 respiration was measured after adding
40 l of malate/glutamate (240/280 mM; assay concentration, 4.8/5.6
mM). Then, 10 l of ADP (100 mM; assay concentration, 0.5 mM) were
added to measure state 3 respiration. After determining coupled respi-
ration, 1 l of carbonyl cyanide p-trifluoromethoxyphenylhydrazone
(FCCP) (0.1 mM; assay concentration, 0.05 nM) was added to the reac-
tion chamber, and respiration was measured in the absence of a proton
gradient. To inhibit complex I activity, a total volume of 3 l (2  1 l)
rotenone (0.1 mM; final concentration, 0.15 nM) was added. Then, 10 l
of succinate (1 M; final concentration, 5 mM) were added, and respiration
was measured. Finally, 8 l of KCN (0.5 M; assay concentration, 2 nM)
were added to inhibit complex IV activity. P301L tau mice and WT
mitochondria were measured in parallel pairs using the same condi-
tions (crossover design).
Complex I Activity—Isolated mitochondria were solubilized in n-
dodecyl -D-maltoside (20%) (Sigma-Aldrich). NADH:hexaammineru-
thenium(III)-chloride (HAR) activity was measured at 30 °C in a buffer
containing 2 mM Na/MOPS, 50 mM NaCl, and 2 mM KCN, pH 7.2,
using 2 mM HAR and 200 M NADH as substrates to estimate the
complex I content. To determine NADH-ubiquinone oxidoreductase ac-
tivity, 100 M n-decylubiquinone (DBQ) and 100 M NADH were used
as substrates, as described previously (29). Oxidation rates of NADH
were recorded with a Shimadzu Multi Spec-1501 diode array spectro-
photometer (340–400 nm  6.1 mM
1 cm1). Complex I activity was
normalized to the complex I content of the mitochondrial preparation
and is given as DBQ/HAR ratio.
Complex IV Activity—Cytochrome c oxidase activity was determined
in intact isolated mitochondria using the Cytochrome c Oxidase Assay
Kit. The colorimetric assay is based on the observation that a decrease
in absorbance at 550 nm of ferrocytochrome c is caused by its oxidation
to ferricytochrome c by cytochrome c oxidase. The Cytochrome c Oxi-
dase Assay was performed as described previously (30).
Preparation of Brain Hemispheres to Determine Lipid Peroxidation
and Antioxidant Enzyme Activities—Mice were anesthetized, and
blood was removed by transcardial perfusion with phosphate-buff-
ered saline, pH 7.4. One hemisphere was minced in 1 ml of cold 20 mM
Tris-buffered saline with 10 strokes in a Potter homogenizer at 1200
rpm (the other hemisphere was fixed in paraformaldehyde). An ali-
quot of this homogenate was diluted 1:1 with Tris-buffered saline and
centrifuged at 3000  g for 10 min at 4 °C, and supernatants were
collected and stored at 80 °C for lipid peroxidation assays. The
remaining homogenate was centrifuged at 8500  g for 10 min at
4 °C, and supernatants were collected and stored at 80 °C until
antioxidant enzyme activity determination.
Assay of Lipid Peroxidation Products—The lipid peroxidation prod-
uct malondialdehyde (MDA) was determined by a photometrical
TABLE I
Protein alterations in P301L tau mice
Protein Accession no.a Fractionb Spot no. Folddifference
Student’s
t test
Mascot
scorec
Proteins involved in mitochondrial respiration and
metabolism
NADH-ubiquinone oxidoreductase 30-kDa subunit Q9DCT2 E2 375 1.62 0.0089 101
ATP synthase D chain Q9DCX2 E2 455 1.90 0.0124 134
ATP synthase D chain Q9DCX2 E2 1457 1.66 0.0026 62
Triosephosphate isomerase P17751 E2 750 1.79 0.0139 71
Inorganic pyrophosphatase (2010317E03Rik protein) Q9D819 E1 576 1.56 0.0007 218
Malate dehydrogenase, cytoplasmic P14152 E1 323 1.58 0.0096 63
Proteins involved in oxidative stress
Peroxiredoxin 6 O08709 E2 38 1.90 0.0076 287
Thioredoxin-dependent peroxide reductase (perioredoxin 3) P20108 E2 978 1.76 0.0007 91
GSTP2 P19157 E2 443 1.68 0.0104 158
GSTMu 1 P10649 E2 622 1.61 0.0145 182
Phospholipid hydroperoxide glutathione peroxidase O70325 E1 1605 1.57 0.0168 98
Synapse-related proteins
DRP-2 O08553 E1 311 1.50 0.0074 305
DRP-2 O08553 E1 1983 1.53 0.0136 103
DRP-2 O08553 E2 1853 1.62 0.0001 222
DRP-2 O08553 E2 140 1.59 0.0000 133
DRP-2 O08553 E2 1289 1.51 0.0001 105
DRP-3 Q62188 E1 1307 1.64 0.0217 81
Synapsin I O88935 E2 1597 1.91 0.0069 172
Synapsin I O88935 E2 2160 1.83 0.0077 140
Septin 11 Q8C1B7 E2 1589 1.70 0.0152 122
Septin 5 (CDCrel-1) Q9Z2Q6 E2 2112 1.59 0.0002 341
Other proteins
Stathmind P54227 E1 2156 1.66 0.0081 55d
MSTI1 (stress-induced phosphoprotein 1) Q60864 E2 1741 1.53 0.0064 113
Stress-induced phosphoprotein 1 Q99L66 E2 1741 1.53 0.0064 101
-Soluble NSF attachment protein (-SNAP) Q9CWZ7 E3 337 1.52 0.0048 491
Endoplasmic reticulum protein Erp29 precursor P57759 E2 778 2.08 0.0058 134
Endoplasmic reticulum protein Erp29 precursor P57759 E2 582 1.72 0.0112 100
Lipoamide acyltransferase component of branched-chain
-keto acid dehydrogenase complex
P53395 E2 1893 1.50 0.0126 87
-Alanine oxoglutarate aminotransferase homologue
(GABA transaminase)
Q8BZA3 E2 240 1.71 0.0107 74
Mus musculus adult male kidney cDNA; gene name;
ethe1, synonym: hsco
Q9DCM0 E2 782 1.56 0.0137 71
Probable D-tyrosyl-tRNA deacylase Q9DD18 E1 251 1.71 0.0004 131
GRB2 adapter protein Q60631 E2 1213 1.57 0.0100 122
Lamin C and C2 P11516 E2 1207 1.86 0.0075 203
Lamin A P48678 E2 1207 1.86 0.0075 203
Paraspeckle protein 1 Q8R326 E2 1207 1.86 0.0075 196
Myeloid leukemia factor 2 Q99KX1 E2 1609 1.56 0.0190 83
UPF0082 Q8K0Z7 E3 178 1.58 0.0086 135
a SWISS-PROT/TrEMBL accession number.
b Sequential extraction fraction where the protein was identified.
c Mascot protein identification score is10*Log (P), where P is the probability that the observed match is a random event. Protein scores greater
than 57 are significant (p  0.05), as based on the mouse database used here.
d This spot was independently identified twice as stathmin with a Mascot score near to significance. Tandem mass spectra were manually
validated, and the identification was considered correct.
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method using the Lipid Peroxidation Assay Kit (Calbiochem) (31). The
colorimetric reaction is a condensation of the aldehyde with 1-methyl-
2-phenylindole, yielding a chromophore with an absorption maximum
at 586 nm. Basal levels of MDA were assayed after incubation of
samples for 30 min at 37 °C, and stimulated MDA levels were deter-
mined under the same conditions in the presence of 50 M FeCl3 in the
sample homogenate.
Cu,Zn-SOD Activity—Cu,Zn-SOD (EC 1.15.1.1) activity was meas-
ured with the Superoxide Dismutase Assay Kit (Calbiochem) (32). To
remove interfering substances and rule out Mn-SOD activity, Cu,Zn-
SOD enzyme activity was assayed after an extraction procedure with
chloroform and ethanol according to the supplier’s manual. SOD activ-
ity was calculated based on the Vs/Vc ratio of the auto-oxidation rates of
the chromophore BXT-01050 measured at 37 °C in the presence (Vs)
and absence (Vc) of sample. The chromophore was measured in a Gene-
sys 5 photometer (Spectronic Instruments, Rochester, NY) at 525 nm. 1
Cu,Zn-SOD activity unit is defined as the activity that doubles the
auto-oxidation background (Vs/Vc  2).
Glutathione Peroxidase Activity—Glutathione peroxidase (cytosolic
glutathione peroxidase, EC 1.11.1.9) activity was measured using the
Cellular Glutathione Peroxidase Assay Kit (Calbiochem) (33) and tert-
butylhydroperoxide as substrate. This reaction is based on the enzy-
matic reduction of hydroperoxide by glutathione peroxidase under con-
sumption of reduced glutathione, which is restored from oxidized
glutathione in a coupled enzymatic reaction by glutathione reductase
(GR). GR reduces oxidized glutathione to reduced glutathione under
consumption of NADPH as reducing equivalents. The decrease in ab-
sorbance at 340 nm due to NADPH consumption was measured in a
Victor2 multiplate reader using a 355-nm filter with 40 nm bandpass. 1
unit of glutathione peroxidase is defined as the activity that converts 2
mol reduced glutathione/min at 25 °C.
GR Activity—The GR (EC 1.8.1.7.) activity was determined using the
Glutathione Reductase Assay Kit (Calbiochem) (34). The enzymatic
activity was assayed photometrically by measuring NADPH consump-
tion during the enzymatic reaction. In the presence of oxidized gluta-
thione and NADPH, GR reduces oxidized glutathione and oxidizes
NADPH to yield NADP, resulting in a decrease of absorbance at 340
nm, which was measured in a Victor2 plate reader. 1 unit of GR is
defined as the activity that reduces 1 mol oxidized glutathione (cor-
responding to 1 mol NADPH)/min at 25 °C.
Statistical Analysis—Data are represented as means  S.E. For
statistical comparison, Student’s t test, one-way ANOVA followed by
Tukey’s post hoc test, or two-way ANOVA followed by Bonferroni post
hoc tests was used. Only p values of 0.05 were considered statisti-
cally significant.
RESULTS
Proteomic Analysis of P301L Tau Transgenic Mice—We per-
formed a proteomic study to carry out an unbiased character-
ization of the consequences of the expression of the human
P301L mutant tau in a transgenic mouse model. To favor the
visualization of a relatively large proportion of different pro-
teins on two-dimensional gels, the brain proteins were sequen-
tially extracted in three fractions according to their solubility,
namely, E1 (soluble proteins), E2 (intermediate soluble pro-
teins), and E3 (less soluble proteins). The proteins of each
fraction from six pairs of hemizygous P301L tau and WT con-
trol mice were first focused in 17-cm IPG strips depending on
their isoelectrical point (pI) and then resolved in the second
dimension by their molecular mass on SDS-PAGE gels. Silver
staining revealed reproducible two-dimensional protein pat-
terns for each sequentially extracted fraction (Fig. 1). Differ-
ences between transgenic andWTmice were highlighted by the
Proteomweaver software, which normalizes the overall spot
intensities and then performs a comparison of every gel with
every other gel. Protein spots that differed by 1.5-fold and
were statistically significant by Student’s t test (p  0.05) were
considered for further investigation. Overall, we found 15 up-
regulated and 22 down-regulated protein spots in P301L tau
transgenic mice as compared with WT controls, including 4 up-
and 4 down-regulated protein spots in fraction E1, 10 up- and
17 down-regulated protein spots in fraction E2, and 1 up- and
1 down-regulated protein spot in the last fraction, E3. After
trypsinization, all but three of these differentially regulated
protein spots were identified by MALDI-TOF/TOF mass spec-
trometry (Table I). Several spots contained more than one
protein, and some were identified as the same protein.
The majority of the regulated spots identified are related to
FIG. 2. Reduced complex V levels in
human P301L FTDP-17 brains. A,
Western blot of human temporal cortex
brain homogenates. Complex V (ATP syn-
thase) is recognized as the bottom band
using an anti-ATP synthase D chain an-
tibody, and the mitochondrial protein
marker porin is recognized as the top
band using an anti-porin antibody. Con-
trol brain homogenates were loaded in
lanes 1 and 2, and P301L FTDP-17 brain
homogenates were loaded in lanes 3–6. B,
complex V/porin percentages for control
and P301L brains after Western blot band
quantification. Sample percentages are
represented in the same order as on the
Western blot described in A.
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either metabolism and mitochondrial respiration, oxidative
stress, or synapse function. In the first category, we identified
one spot as the 30-kDa subunit of NADH-ubiquinone oxi-
doreductase (electron transport chain complex I) and two spots
as the ATP synthase D chain (complex V). All three spots were
down-regulated as well as the metabolism-related spots, triose-
phosphate isomerase, a glycolytic enzyme, and the cytoplasmic
malate dehydrogenase involved in the malate-aspartate shut-
tle providing a metabolic coordination between cytosol and
mitochondria. In contrast, a spot identified as inorganic pyro-
phosphatase was up-regulated. Associated with oxidative
stress, spots representing the antioxidant enzymes peroxiredoxin
6, perioredoxin 3 (thioredoxin-dependent peroxide reductase),
glutathione S-transferase (GST) P2 and Mu1, and phospholipid
hydroperoxide glutathione peroxidase were all down-regulated.
In the last functional category, we found up-regulated spots
related to synaptic function, such as the synaptic vesicle-asso-
ciated proteins synapsin I, CDCrel-1, and septin 11, the axonal
growth-related protein dihydropyrimidinase-related protein
(DRP)-2, and another member of the dihydropyrimidinase fam-
ily, DRP-3. Further differentially regulated spots (Table I) in-
cluded stathmin, a microtubule-destabilizing protein; MSTI1,
the murine homologue of hop (HSP70/HSP90 organizing pro-
tein); and growth factor receptor-bound protein 2 (GRB2), an
adapter protein in signaling pathways. Therefore, P301L tau
expression results in distinct modifications of the brain pro-
teome, suggesting alterations in the mitochondrial electron
transport chain, cellular antioxidant capacities, and synaptic
properties.
Human P301L FTDP-17 Brains Show Decreased Complex V
Levels—Because the proteomics comparison of the P301L tau
and WT control mice revealed a significant decrease of two
FIG. 3. Impaired depolarization and reduced mitochondrial complex I activity in P301L tau mice. A, use of specific complex inhibitors
reveals a significantly reduced depolarization of mitochondria from 12-month-old P301L tau mice after treatment with the complex I inhibitor
rotenone (Rot) and the complex V inhibitor oligomycin (Oligo) (*, p  0.05; **, p  0.01 versus corresponding WT control mice, Student’s t test).
A similar tendency was also found by inhibition of complex II with thenoyltrifluoroacetone, inhibition of complex III with antimycin (Ant), and
inhibition of complex IV with NaN3. Two-way ANOVA reveals a significant effect of the transgene (p  0.01) and individual complexes (p  0.001),
with no interaction between the two parameters. BD, complex I activity in cerebral mitochondria from 12-month-old P301L tau mice and
age-matched WT control mice. B, reduced NADH-ubiquinone oxidoreductase (NADH:DBQ) activity in mitochondria of P301L tau mice (*, p  0.05
versus WT control mice, Student’s t test). C, unaltered NADH:HAR activity. D, complex I activity was normalized to the complex I content of the
mitochondrial preparation and is given as DBQ/HAR ratio (*, p  0.05 versusWT control mice, Student’s t test). E, unaltered complex IV activity.
All values represent the means  S.E. from n  6–8 animals/group.
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spots identified as the ATP synthase D chain, we looked at
complex V levels in human FTDP-17 patient brains carrying
the P301L tau mutation. Four P301L FTDP-17 brain and two
control brain homogenates were examined by Western blot
(Fig. 2A). We used the mitochondrial protein marker porin to
control for variations in mitochondrial amounts. Normalization
of complex V levels with porin levels showed a significant
decrease in complex V levels in all P301L brain samples com-
pared with control brains (Fig. 2B). Similar control complex
V/porin percentages were found in three other control brain
samples (data not shown). On average, we measured a 62.3%
reduction of complex V levels in P301L FTDP-17 brains com-
pared with control brains. The decreased levels of complex V in
human P301L FTDP-17 brains confirm the proteomics obser-
vation made in the P301L tau transgenic mice and suggest that
the P301L mutant tau pathology potentially causes a specific
mitochondrial dysfunction in humans as well as in mice.
P301L Tau Mice Exhibit Mitochondrial Respiratory De-
fects—We examined the metabolic capacity and function of
cerebral mitochondria from P301L tau transgenic mice. Con-
sistent with the down-regulation of subunits of mitochondrial
electron transport chain complexes I and V, treatment with
specific complex inhibitors showed a general reduction in mi-
tochondrial depolarization of P301L tau brain cells compared
with WT and specifically showed a significantly reduced depo-
larization after inhibition of complexes I and V (Fig. 3A). Using
a direct measurement of complex I activity, we observed a
significant reduction of NADH-ubiquinone oxidoreductase
(NADH:DBQ) activity in mitochondria of 12-month-old P301L
tau mice (Fig. 3B), whereas NADH:HAR activity (Fig. 3C) was
not different, indicating that complex I content is similar in
P301L tau andWT control mice. Thus, P301L tau mitochondria
present a functional defect of complex I activity with a reduc-
tion of 30.75% as revealed after normalization of complex I
activity with complex I content (Fig. 3D). In contrast, complex
IV showed no differences in the cytochrome c oxidase activity
between WT and P301L tau transgenic mice (Fig. 3E).
In addition, we determined the state 3 and state 4 respira-
tion using substrates for complex I (glutamate/malate) (Fig. 4,
A and B). State 3 respiration measures the capacity of mito-
chondria to metabolize oxygen and the selected substrate in the
presence of a limited quantity of ADP, which is a substrate for
the ATP synthase (complex V). State 4 respiration measures
respiration when all ADP is exhausted, and it is associated
with proton leakage across the inner mitochondrial membrane.
Therefore, it represents a “basal-coupled” rate of respiration.
Whereas state 3 and state 4 respiration remained unchanged
with complex I substrates in 12-month-old P301L tau mice
(Fig. 4B, top panel), a significantly reduced state 3 respiration
could be observed in 24-month-old P301L tau mice (Fig. 4, A
and B, bottom panels), leading to a markedly reduced respira-
tory control ratio compared with age-matched WT mice (Fig.
5A). The respiratory control ratio provides a measure for the
efficiency of coupling of the mitochondrial respiratory chain,
FIG. 4.Oxygen electrode reveals a reduction of O2 consumption of P301L tau mitochondria during aging. A, representative diagrams
of measurement of oxygen (O2) consumption in mitochondria from a 24-month-old WT control (top panel) and an age-matched P301L tau mouse
(bottom panel) demonstrating a decrease in the total O2 concentration with time. O2 flux and consumption by mitochondria (mito) was measured
after addition of different agents (marked by arrows): malate/glutamate (mal/glu; state 4), ADP (state 3), FCCP, rotenone (rot), succinate (suc),
and KCN. B, O2 consumption in freshly isolated cerebral mitochondria from 12-month-old mice (top panel) and 24-month-old mice (bottom panel),
respectively. State 4 was measured after adding malate/glutamate. Then, ADP was added to measure state 3 respiration. After determining
coupled respiration, FCCP was added, and respiration was measured in the absence of a proton gradient. To inhibit complex I activity, rotenone
was added. Then, respiration was measured after the addition of succinate. Finally, complex IV activity and O2 consumption were inhibited by
treatment with KCN. Two-way ANOVA reveals a significant effect of the transgene (p  0.05) on coupled (state 3 and 4) and FCCP-induced
uncoupled respiratory rates of mitochondria from 24-month-old P301L tau mice compared with age-matched WT controls by using the specific
complex I substrates malate/glutamate. Thus, aged but not 12-month-old P301L tau mice exhibit a significant impairment of complex I-related
respiration (*, p  0.05 versus corresponding WT control, Student’s t test), whereas respiratory rates after addition of the complex II substrate
succinate are unchanged. Values represent the means  S.E. from n  4 animals/group (measurement of WT control and P301L tau in parallel).
All experiments were performed in duplicates.
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indicating that the relative efficiency of metabolic coupling of
the electron chain complexes is impaired during aging in
P301L tau mice. In addition, after uncoupling with FCCP, the
respiratory rate in the absence of a proton gradient was signif-
icantly diminished in 24-month-old P301L tau mice (Fig. 4B,
bottom panel), indicating a reduced maximum capacity of the
electron transport chain. After complete inhibition of complex I
with rotenone, succinate was added as a substrate for complex
II. No difference in respiratory rate could be observed between
transgenic and WT mice, showing that complex II is not im-
paired by P301L tau. In accordance with the respiratory control
ratio, ATP levels of cerebral cells were unchanged in 12-month-
old P301L tau transgenic mice but significantly reduced with
aging (Fig. 5B). Together, these results suggest that P301L tau
mice exhibit an initial defect in mitochondrial function with
reduced complex I activity, which, with age, is translated into
a mitochondrial respiration deficiency with diminished ATP
synthesis corresponding to reduced complex V activity.
Mitochondrial Dysfunction Is Not Coupled to Alterations in
the Number of Mitochondria in P301L TauMice—Evaluation of
the number of mitochondria in cerebral brain cells revealed no
difference between P301L tau and WT mice either in the cer-
ebrum (Fig. 6A) or in the cerebellum (data not shown). In
addition, co-immunostaining of mitochondria and microtubules
and subsequent counting of the mitochondria in proximal and
distal parts of neurites in the CA1 region of the hippocampus
also showed no variation between P301L tau andWTmice (Fig.
6B). These data suggest that mitochondrial dysfunction is not
associated with reduced mitochondrial numbers or significant
changes in transport of mitochondria along neurites.
Increased Tau Pathology Causes Higher Oxidative Stress,
Modified Lipid Peroxidation Levels, and Up-regulation of An-
tioxidant Enzyme Activities in P301L Tau Mice—In P301L tau
mice, these mitochondrial defects are associated with increased
ROS formation because both staining with DHE for detection of
superoxide anions and staining with H2DCF-DA for detection
of cytosolic peroxides were increased (Fig. 7, A and B). In-
creased ROS levels could be detected already in 12-month-old
P301L tau mice but were more pronounced and statistically
significant in 24-month-old mice, correlating with the age-spe-
cific increase in tau pathology. As a measure of free radical
damage to critical cellular components, levels of MDA as lipid
peroxidation end product were determined. Despite increased
ROS levels, basal levels of MDA were decreased in 24-month-
old hemizygous P301L tau mice and more pronounced in ho-
mozygous mice, indicating that ROS levels are met by adequate
antioxidant defenses in these mice (Fig. 7C). However, upon
stimulation with ferric iron, increased MDA levels were formed
in P301L tau mice (Fig. 7D). This effect was already observed
in 12-month-old mice but was more pronounced and statisti-
cally significant in 24-month-old homozygous mice. Further-
more, basal and stimulated MDA levels remained unchanged
in the cerebellum of 24-month-old hemi- and homozygous
P301L tau and WT mice (data not shown). Because P301L tau
is expressed at very low levels in the cerebellum (7), we can
conclude that modifications in lipid peroxidation are specifi-
cally caused by the presence of the P301L tau protein. Hence,
the presence of mutant tau impairs antioxidant defense under
conditions of increased oxidative stress.
As a direct measure of antioxidant defense, activities of
antioxidant enzymes were determined. Although no significant
changes were observed in 12-month-old mice, 24-month-old
homozygous P301L tau mice displayed increased activities of
Cu,Zn-SOD and GR (Fig. 8, top and bottom), whereas the ac-
tivity of glutathione peroxidase was not significantly increased
(Fig. 8, middle). The increased enzyme activities may provide
protection against ROS damage under basal conditions, but
they are obviously not sufficient to eliminate lipid peroxidation
damage caused by the in vitro stimulation of brain homoge-
nates with ferric iron. It is important to note that modified lipid
peroxidation levels and increased antioxidant enzyme activi-
ties are dependent on the levels of P301L tau pathology be-
cause these changes were only detected as significant in old
homozygous P301L tau mice.
A Insult Causes Increased Membrane Potential Reduction
in P301L Tau Mitochondria—Extracellular A treatment of
PC12 cells has been shown to lead to a significant decrease in
mitochondrial membrane potential (35). To investigate
whether brain cells from P301L tau mice are more susceptible
to A, we measured the mitochondrial membrane potential of
isolated cortical brain cells with and without A treatment.
Interestingly, the basal mitochondrial membrane potential was
still conserved in cerebral cells from P301L tau mice. However,
secondary insult with A1–42 resulted in a higher reduction in
membrane potential in P301L tau mitochondria than in WT
mitochondria (Fig. 9A). Importantly, this effect is brain region-
specific and therefore probably dependent on the presence of
P301L tau because cells from cerebellum with very low P301L
tau expression levels were not vulnerable to this damage (Fig.
9B). These data suggest a synergistic action of A and tau
pathology on mitochondrial function.
FIG. 5. Reduced respiratory control ratio and impaired ATP
synthesis in P301L tau mice with aging. A, reduced respiratory
control ratio in 24-month-old P301L tau mitochondria (*, p  0.05
versus age-matched WT control mice, Student’s t test), indicating an
impaired efficiency of electron transport in aging. Values represent
means  S.E. from n  4 animals/group. All experiments were done in
duplicates. B, in accordance, cerebral ATP levels are significantly re-
duced in 24-month-old P301L tau mice (*, p  0.05 versus age-matched
WT control mice, Student’s t test). Two-way ANOVA reveals a signifi-
cant effect of the transgene (p  0.05) on ATP levels. Values represent
means  S.E. from n  6–7 animals/group.
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DISCUSSION
The P301L mutation of tau is one in a set of mutations
implicated in FTDP-17 (36). This mutation reduces the ability
of tau to interact with microtubules and promotes the assembly
of tau into filaments in vitro. In our P301L tau transgenic mice,
tau filaments start to accumulate at about 6 months of age,
preceded by distinct hyperphosphorylation of tau (7, 20). Fur-
thermore, the tau pathology causes specific behavioral deficits
in the mice related to the amygdala, an area with prominent
NFT formation (37).
Proteomics is becoming more and more widely used to study
brain changes under physiological and pathological conditions
such as in AD (38, 39). Considering the complexity of brain
tissue, we adapted a sequential extraction method to separate
the brain proteins according to solubility before proteomic anal-
ysis (40). This approach, followed by functional analysis of the
P301L tau mice, suggests that tau accumulation, in the ab-
sence of massive NFT formation, induces a mitochondrial dys-
function. The down-regulation of nuclear encoded subunits of
electron transport chain complexes I and V was accompanied
by a reduced depolarization of mitochondria from 12-month-old
P301L tau mice after treatment with the complex I inhibitor
rotenone and the complex V inhibitor oligomycin. We could also
demonstrate a direct decrease in complex I activity. At this age,
the other mitochondrial respiratory chain complexes seemed to
be able to compensate because the respiratory control ratio and
mitochondrial membrane potential remained unchanged. How-
ever, following the increase of tau pathology with aging, this
compensation is no longer sufficient, and mitochondria from
24-month-old P301L tau mice exhibited an impaired efficiency
of coupling between the mitochondrial respiratory chain com-
plexes, diminished capacity in electron transport, and a signif-
icant reduction in ATP levels. In particular, the reduction in
state 3 respiration reflects a reduced capacity of mitochondria
to metabolize oxygen and the complex I substrate in the pres-
ence of a limited quantity of ADP. Thus, there is also a clear
complex I deficiency in the mitochondrial respiration at 24
months of age.
Our results correlate with previous studies on AD, suggest-
ing partial mitochondrial uncoupling (41), modifications of mi-
tochondrial encoded complex I subunit mRNA (42, 43), and
reduction in protein levels of the 24- and 75-kDa subunits of
complex I (11) as well as diminished ATP synthase (complex V)
levels (10). As demonstrated in primates, complex I activity has
been shown to be reduced with aging, which could potentially
intensify complex I activity defects in the P301L tau mice (44).
Furthermore, we could show a clear-cut reduction in levels of
complex V in human P301L FTDP-17 brains as compared with
control human brains. This important finding confirming the
decrease in complex V identified twice in our proteomics anal-
ysis of the P301L tau mouse argues in favor of a potential
mitochondrial dysfunction in human FTDP-17 patients. This
result also emphasizes the relevance of our P301L tau mouse as
a model of the human tau pathology.
Our proteomic analysis also revealed modifications in lev-
els of triosephosphate isomerase, cytoplasmic malate dehy-
drogenase, and inorganic pyrophosphatase, implying a
broader metabolic disorder possibly encompassing the glycol-
ysis cycle. The glycolytic enzyme triosephosphate isomerase
can bind to microtubules (45), and higher levels of nitrated
triosephosphate isomerase have been found in AD brains
(46). Consistent with an overall metabolic failure, several
FIG. 6. Unchanged number of mitochondria. A, measurement of the number of mitochondria using the cell-permeable mitochondrion-
selective dye Mitotracker Green reveals no differences between P301L tau and WT mice in cerebrum. Values represent the means  S.E. from n 
8 animals/group. B, immunostaining of mitochondria and microtubules in CA1 hippocampal brain sections with anti-porin (Cy3; red) and
anti-tubulin antibodies (Cy2; green) again reveals no statistical difference in mitochondrial neuritic numbers in proximity or distal to the cell body
between 18-month-old P301L tau andWTmice. Values represent the means S.D. from n 4 animals/group, in which mitochondria were counted
in four different neurites per animal. Scale bar, 50 m.
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reports using positron emission tomography revealed re-
duced glucose metabolism in AD and frontotemporal demen-
tia brains (12, 13, 47–49). Notably, high levels of phospho-
rylated tau have been linked to glucose hypometabolism in
mild cognitively impaired patients (50).
Together, this evidence supports a role of tau pathology in
mitochondrial and metabolic dysfunction. However, it remains
unclear how tau accumulation mediates these changes. Over-
expression of WT tau in cell culture caused impairment of plus
end-directed transport, resulting in a reduction of mitochon-
dria levels in the neurites (51). Although we cannot exclude the
possibility of this occurring in the P301L tau mice, the number
of mitochondria in neurites counted in proximity or distally to
the cell body did not vary significantly compared with WT
numbers. Furthermore, the total amount of mitochondria re-
mained unchanged as measured in brain cells of transgenic
compared with control mice. This suggests that either P301L
tau induces a different pathological mechanism than overex-
pressed WT tau or that tau action on mitochondria transport in
cell culture cannot be extrapolated over to the mouse model.
Consistent with our findings, similar numbers of mitochondria
were reported in NFT-bearing and non-NFT-bearing cells in
AD (52). Alternatively, tau accumulation could have direct
repercussions on the mitochondria because the accumulation of
increasingly insoluble ATP synthase -chain together with
NFTs has been shown in AD brains, whereas detergent soluble
levels were reduced (53). Overall, it is important to note that
the mitochondrial pathology in the P301L tau mice observed in
this study is unlikely to be a direct consequence of tau hyper-
phosphorylation. Indeed, the transgene levels of expression in
these mice are relatively low (7), and depletion of ATP solely
due to tau hyperphosphorylation would be improbable.
We furthermore demonstrate that accumulation of P301L
tau causes significant modifications in the oxidative state of the
brain. ROSmeasurements revealed increased levels of cytosolic
H2O2 and superoxide anion radicals in 2-year-old P301L tau
mice. These increased ROS levels may be a direct consequence
of reduced complex I activity in P301L tau mice because inhi-
bition of complex I can lead to increased superoxide formation
(54). The increased activity of Cu,Zn-SOD measured in P301L
tau mice should ameliorate the accumulation of superoxide but
also gives rise to H2O2, which is then insufficiently processed
by glutathione peroxidase, leading to accumulation of perox-
ides. Accordingly, the relative increase in H2O2 in P301L tau
mice was much more pronounced than the increase in super-
oxide radicals. Somewhat unexpectedly, along with increased
tau pathology, we observed decreased levels of the lipid peroxi-
dation product MDA as a marker for ROS damage to cellular
membranes in old homozygous P301L tau mice, despite in-
creased levels of ROS. One potential explanation for this dis-
crepancy could be that the cells affected by lipid peroxidation
are removed by apoptosis, although we could not detect major
differences in levels of apoptotic cells detected by terminal
deoxynucleotidyl transferase-mediated nick end labeling stain-
ing (data not shown). Because several steps lead from ROS
accumulation to lipid peroxidation damage, another possibility
would be that the up-regulation of antioxidant activities of
Cu,Zn-SOD and GR in P301L tau mice may intercept ROS
before they can critically damage membranes. As previously
reported, rising Cu,Zn-SOD and GR activities in aged mouse
FIG. 7. Increased ROS production. A, increases in superoxide anion radicals determined by DHE oxidation. Fluorescence (in arbitrary units)
normalized for protein content in brain cells from hemizygous P301L tau mice was measured after incubation of samples with DHE for 15 min.
Two-way ANOVA: p  0.01, effect of transgene; age and interaction were not significant. Bonferroni post hoc test: *, p  0.05, WT versus
hemizygous P301L tau mice. B, increases in cytosolic H2O2 determined by H2DCF oxidation. Fluorescence in brain cells from hemizygous P301L
tau mice was measured after incubation of samples with H2DCF-DA for 15 min. Two-way ANOVA: p 0.01, effect of transgene; age and interaction
were not significant. Bonferroni post hoc test: *, p 0.05, WT versus hemizygous P301L tau mice. C, reduced lipid peroxidation in P301L tau brains
under basal conditions determined by MDA levels (nmol/mg protein). Two-way ANOVA: p 0.01, effect of transgene; p 0.05, age group; p 0.05,
interaction. Bonferroni post hoc test: ***, p  0.001, WT versus homozygous P301L tau mice (P301L/P301L). D, increased lipid peroxidation under
stimulated conditions in 24-month-old homozygous P301L tau mice. Formation of MDA (nmol/mg protein) in brain homogenates after a 30-min
incubation with FeCl3 is increased in samples from P301L tau mice. Two-way ANOVA: p  0.05, effect of transgene; age and interaction were not
significant. Bonferroni post hoc test: *, p  0.05, controls versus homozygous P301L tau mice. All values represent means  S.E. from n  6–9
animals/group (except for 12-month-old homozygous animals, n  3).
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brains can protect against lipid peroxidation (55). Further-
more, SOD can prevent lipid peroxidation both in vitro and in
vivo (56–60). Similarly, increased GR activity in P301L tau
mice may protect against accumulation of MDA by increasing
levels of the antioxidant reduced glutathione. In several exper-
imental models, increased levels of reduced glutathione were
associated with lower levels of lipid peroxidation products and
vice versa (61, 62). Upon in vitro stimulation, however, higher
levels of MDA were formed in homozygous P301L tau brain
homogenates. Obviously, the increased activities of Cu,Zn-SOD
and GR were not sufficiently protective under these conditions.
This may be explained by a relative lack in glutathione perox-
idase activity because the accumulation of H2O2 observed in
brains from P301L tau mice combined with the exogenously
added ferric iron can lead to increased formation of hydroxyl
radicals via Haber-Weiss and Fenton reactions. Reports on
lipid peroxidation in brains from patients with tauopathies are
inconsistent. Although increased levels of the lipid peroxida-
tion product 4-hydroxynonenal were found in patients with
progressive supranuclear palsy (63), and tau was co-localized
with MDA immunoreactivity in AD patients (64), another
study reported increased lipid peroxidation products specifi-
cally in AD patients, but not in patients with frontotemporal
dementia (65). Therefore, tau pathology may not be associated
inevitably with lipid peroxidation processes in human brain
tissue, consistent with our observations in P301L tau mice.
Most studies have reported an up-regulation of antioxidant
enzyme activities in AD (66). These changes were most pro-
nounced in brain regions that are severely affected by AD
pathology (66–68).
Our proteomic analysis also suggests changes in cellular
antioxidant mechanisms as shown by variations in spots rep-
resenting the antioxidant enzymes perioredoxin 3, peroxire-
doxin 6, GST P2 and Mu1, and phospholipid hydroperoxide
glutathione peroxidase. Peroxiredoxin reduces peroxides in-
cluding H2O2, GST catalyzes the conjugation of reduced glu-
tathione to a large number of molecules, and phospholipid
hydroperoxide glutathione peroxidase directly reduces peroxi-
dized phospholipids in membranes (69). Although all these
protein spots were down-regulated in the P301L tau mouse,
this does not necessarily reflect enzyme activities. Besides,
under oxidative conditions, these antioxidant enzymes are
prone to oxidative modifications represented by a set of distinct
spots on two-dimensional gels as suggested for peroxiredoxin,
which undergoes overoxidation. Interestingly, AD brains show
decreased GST activity (70) and GST Omega1 mRNA levels in
AD (43), and single nucleotide polymorphisms in GST Omega1
are associated with age at onset in AD (43).
Hence, both our functional and proteomic data indicate a
complex regulation and potential malfunction of the cellular
FIG. 8. Altered levels in detoxifying enzymes. Top, increased
Cu,Zn-SOD activity in 24-month-old homozygous P301L tau mice. Two-
way ANOVA: effect of transgene was not significant; p  0.05, age
group; p  0.05, interaction. Bonferroni post hoc test: *, p  0.05,
controls versus homozygous P301L tau mice. Middle, glutathione per-
oxidase activity. Two-way ANOVA: p  0.05, effect of transgene; age
group and interaction were not significant. Bottom, increased GR ac-
tivity in 24-month-old homozygous P301L tau mice. Two-way ANOVA:
p  0.05, effect of transgene; age group and interaction were not
significant. Bonferroni post hoc test: *, p  0.05, controls versus homozy-
gous P301L tau mice. Values represent means  S.E. from n  6–9
animals/group (except for 12-month-old homozygous animals, n  3).
FIG. 9. Brain region-specific decrease of membrane potential
after secondary insult with 50 nM A. Aged, aggregated prepara-
tions of A1–42 were given to brain cells as secondary insult. An in-
creased reduction of 	m was observed with the addition of A to
cerebral cells (A) (*, p  0.05 versus WT control mice, Student’s t test),
but not with cerebellar cells (B) from 12-month-old P301L tau mice.
Two-way ANOVA reveals a significant effect of the transgene (p 0.05)
on changes of mitochondrial membrane potential in cerebral cells. Val-
ues represent the means  S.E. from n  6–7 animals/group.
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antioxidant defense mechanisms in response to increased ROS
levels in this mouse model. Because mitochondrial dysfunction
appears prior to oxidative stress, this suggests that it is prob-
ably the initiating factor. However, we can speculate that both
mitochondrial dysfunction and oxidative stress act in synergy,
creating a vicious cycle. Indeed, increases in ROS and antiox-
idant enzyme dysfunction could affect the integrity of the mi-
tochondria and, in particular, the electron transport chain (35).
Furthermore, glutathionylation of complex I in oxidative con-
ditions leads to increased superoxide production (71). Another
possible consequence of higher oxidative stress levels could be
an acceleration of tau pathology (72, 73). Moreover, tau can be
readily oxidized by H2O2 to form disulfide-linked species that
manifest reduced propensity to promote microtubule assembly
(74). Oxidized tau then becomes a substrate of the thioredoxin
reductase and glutathione/glutaredoxin reductase systems (74,
75). Thereby, we can speculate that the accumulation of oxi-
dized P301L tau might overload these antioxidant regenerat-
ing systems, causing further oxidative stress.
Results from our proteomic study further suggest a potential
synaptic dysfunction because we found an up-regulation of a
series of synapse-related proteins. The identified DRP-2 is
known to promote axonal growth by interaction with the tubu-
lin heterodimer and has also been shown to induce neurite
formation (76, 77). Synapsin I is thought to regulate the reserve
pool of synaptic vesicles (78). The septin member CDCrel-1 is
found mainly in inhibitory presynaptic terminals and inhibits
exocytosis (79, 80). Interestingly, both DRP-2 and septin asso-
ciate with NFTs in AD (81, 82). Therefore, in response to tau
pathology, the transgenic mouse neurons may be attempting a
compensatory mechanism by increasing synaptic vesicle con-
trol proteins and potentially aberrant synaptic sprouting. In-
deed, although advanced stages of AD are associated with
synaptic loss, an initial increase in synaptic protein levels in
AD brains was observed that was correlated with the appear-
ance of the tau pathology but not with A plaques (83). On the
contrary, a decrease of synaptic proteins occurred only after the
appearance of the full spectrum of tau and A pathology. Al-
though it is uncertain exactly how tau mechanistically affects
synapses, we can postulate that the mutant tau acts either by
modifying microtubule stability and axonal transport or by
inhibiting energy production through complex I in the syn-
apses. Indeed, a reduction in the activity of complex I by only
25% has been shown to impair energy metabolism in synaptic
mitochondria (84), whereas at least a 72% reduction in com-
plex I activity is needed before energy metabolism is im-
paired in non-synaptic mitochondria (85). In this study, our
mitochondrial isolation does not include synaptic mitochon-
dria. It would be interesting to measure complex I activity
and mitochondrial respiration in a pure synaptosomal mito-
chondrial preparation.
In addition to the three major categories (metabolism-related
proteins, antioxidant enzymes, and synaptic proteins), we
could identify, by proteomics, several other proteins modified
by the presence of the P301L tau and potentially linked to AD
pathology. The up-regulated MSTI1 mediates assembly of
HSP70/HSP90 (86). A proteomic study has shown modifica-
tions in various chaperone levels in AD brain (87). In addition,
levels of HSP B-crystallin, HSP27, and HSP60 were found to
be increased in tauopathies with glial pathology (88). De-
creased in the P301L tau mouse brain proteome pattern, GRB2
is an adapter protein that is involved in the activation of the
mitogen-activated protein kinase signaling pathway. Interest-
ingly, AD brains show higher amounts of GRB2 than control
brains (89, 90). Levels of the microtubule-destabilizing protein
stathmin have been found to be negatively correlated with NFT
numbers in AD neocortex (91) and were also down-regulated in
the P301L tau mice.
Finally, our data from the proteomic and functional study of
the P301L tau transgenic mouse should help to better distin-
guish between the respective pathological actions of A and tau
protein. Numerous studies indicate that A also causes oxida-
tive stress and mitochondrial malfunction (35, 92–94). In par-
ticular, A has been shown to generate free radicals in vitro
(95) and reduces mitochondrial respiration through inhibition
of cytochrome c oxidase activity (35, 96). We show here that A
causes increased reduction of mitochondrial membrane poten-
tial in P301L tau mouse cerebrum compared with wild-type
cerebrum. Importantly, this is not observed in the cerebellum
of P301L tau mice, a brain area with very low levels of trans-
genic tau. This could partially explain why injection of fibrillar
A peptide into the hippocampus of P301L tau mice accelerated
NFT formation in the amygdala, in line with the amyloid
cascade hypothesis (20). Therefore, both tau and A accumu-
lation probably act in synergy on oxidative stress and mito-
chondrial dysfunction.
In conclusion, our study increases understanding of the path-
ological consequences of tau alone, suggesting that not only A
but also tau accumulation acts on the metabolism of the brain
and the oxidative conditions in AD. This implies that it will be
important to address the treatment and/or removal of both A
and tau pathology to efficiently treat AD patients.
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